Alexion Pharmaceuticals Inc.

:ALXN   3:59:59 PM EDT
182.31
+2.86 (+1.59%)
Products, Regulatory

Alexion Announces Positive Topline Results From Phase 3 Study Of Ultomiris® In Adults With Generalized Myasthenia Gravis

Published: 07/15/2021 20:24 GMT
Alexion Pharmaceuticals Inc. (ALXN) - Alexion Announces Positive Topline Results From Phase 3 Study of Ultomiris® (ravulizumab-cwvz) in Adults With Generalized Myasthenia Gravis (gmg).
Alexion Pharmaceuticals Inc - Study Met Primary Endpoint of Change From Baseline in Mg-adl Total Score at Week 26.
Alexion Pharmaceuticals Inc - Ultomiris Demonstrated Compelling Efficacy As Early As Week 1, Sustained for 52 Weeks.
Alexion Pharmaceuticals Inc - Ultomiris Was Well Tolerated With a Safety Profile Consistent With That Observed in Phase 3 Studies.
Alexion Pharmaceuticals Inc - Based on Study Results, Co Plans to Make Regulatory Filings in U.S., European Union and Japan in Late 2021/early 2022.